Guidance

Flu vaccines for the 2023 to 2024 season

Updated 8 August 2023

Applies to England

© Crown copyright 2023

This publication is licensed under the terms of the Open Government Licence v3.0 except where otherwise stated. To view this licence, visit nationalarchives.gov.uk/doc/open-government-licence/version/3 or write to the Information Policy Team, The National Archives, Kew, London TW9 4DU, or email: psi@nationalarchives.gov.uk.

Where we have identified any third party copyright information you will need to obtain permission from the copyright holders concerned.

This publication is available at https://www.gov.uk/government/publications/flu-vaccines-for-the-current-season/flu-vaccines-for-the-2023-to-2024-season

Flu vaccines

Flu vaccines available for the 2023 to 2024 season:

Vaccine Manufacturer Licensed from age
Cell-based Quadrivalent Influenza Vaccine (QIVc) ▾[footnote 1], [footnote 2]
Egg-free		 CSL Seqirus licensed from 2 years of age
Fluenz Tetra, live attenuated influenza vaccine (LAIV) [footnote 1] AstraZeneca licensed from 2 years to under 18 years of age
Quadrivalent Influenza Vaccine, egg-grown (QIVe) [footnote 3] Sanofi licensed from 6 months of age
Influvac sub-unit Tetra, Quadrivalent Influenza Vaccine, egg-grown (QIVe) [footnote 3] Viatris (formerly Mylan) licensed from 6 months of age
Supemtek▾, recombinant Quadrivalent Influenza Vaccine (QIVr) [footnote 2]
Egg-free		 Sanofi licensed from 18 years of age
Adjuvanted Quadrivalent Influenza Vaccine▾ (aQIV) [footnote 2] CSL Seqirus licensed from 65 years of age

Eligible groups

Eligible groups for the 2023 to 2024 season:

  • aged 2 and 3 years on 31 August 2023
  • eligible school aged children (Reception to Year 11)
  • those aged 6 months to under 65 years in clinical risk groups
  • pregnant women
  • all those aged 65 years and over
  • those in long-stay residential care homes
  • carers, those in receipt of carer’s allowance or main carer of an older or disabled person
  • household contacts of immunocompromised individuals
  • frontline health and social care staff

See the Green Book Influenza chapter 19 for full details on eligible groups.

Age group and vaccine type

6 months to under 2 years in a clinical risk group

Give QIVc (Cell-based quadrivalent influenza vaccine) ‘off label’ use.

If QIVc is not available give QIVe.

2 years to under 18 years in eligible year groups or in a clinical risk group

If there are no contraindications to LAIV, give quadrivalent LAIV nasal spray suspension.

If LAIV is contraindicated or otherwise unsuitable [footnote 4], give QIVc. If QIVc is not available give QIVe.

18 years to under 65 years [footnote 5] in a clinical risk group [footnote 6] and pregnant women

Give QIVc or QIVr.

If QIVc or QIVr is not available give QIVe.

65 years and over

Give aQIV [footnote 5] or QIVr.

If aQIV or QIVr is not available give QIVc.

Resources

Further information is available in the Green Book Influenza chapter 19.

Resources for the current flu vaccination programme are available to download or order.

A PDF poster version of this guide, showing the packaging of the different types of flu vaccines, is available download.

  1. QIVc and LAIV for eligible children (under 18 years of age) available to order from ImmForm. ↩ ↩2

  2. Black triangle scheme ↩ ↩2 ↩3

  3. QIVe is not supplied by ImmForm. ↩ ↩2

  4. If the parent of an eligible child declines LAIV because of its porcine gelatine content (and they understand that it is more effective in the programme than the injected vaccines), they can request an alternative injectable vaccine. QIVc is available to order from ImmForm for these children. ↩

  5. Those who become 65 years of age before 31 March 2024 may be offered aQIV ‘off-label’. ↩ ↩2

  6. Or household contact of an immunocompromised individual. ↩

Back to top